Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Plasma cell 9Thoracic 2Other hematologic neoplasm 2CNS 2Breast 2Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 101Specimen Handling 82pembrolizumab 78enzalutamide 63Nivolumab 60Gemcitabine 54Docetaxel 52apalutamide 42Radiosurgery 41Abiraterone Acetate 40Prednisone 39Androgen Antagonists 39Biopsy 37darolutamide 36Cisplatin 35cabozantinib 33Radiotherapy 32Carboplatin 29Pluvicto 28enfortumab vedotin 27abiraterone 27Ipilimumab 25Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 19X-Rays 19Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tocilizumab × Genitourinary × 90 days × Clear all
NCT03821246 2026-06-04

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

University of California, San Francisco

Phase 2 Recruiting
68 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡